William T. Symonds - Concepedia

Author

William T. Symonds

Also Known As

Marder, Karen, W Symonds, W T Symonds, W. Symonds, W. T. Symonds, W.T. Symonds, William Symonds, William T Symonds, William T. Symonds

132

Publications

17.9K

Citations

H-Index

Concepts

All Affiliations

Gilead Sciences (United States)Texas Liver Institute Johns Hopkins University Puerto Rico Community Foundation Cornell University

About

William T. Symonds is an author at Gilead Sciences (United States) specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	47	5K
2	Natural Sciences	1	1	36
3	Public Health	1	1	36
4	Allergy	1	1	129
5	Cell Biology	1	1	14

William T. Symonds

Publications

17.5K

Citations

H-Index

Page 1

	Year	Citations
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection Eric Lawitz, Alessandra Mangia, David Wyles, New England Journal of Medicine	2013	1.8K
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection Nezam H. Afdhal, Stefan Zeuzem, Paul Y. Kwo, New England Journal of Medicine	2014	1.7K
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection Nezam H. Afdhal, K. Rajender Reddy, David R. Nelson, New England Journal of Medicine	2014	1.3K
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection Mark Sulkowski, David Gardiner, M. Rodríguez‐Torres, New England Journal of Medicine	2014	1.2K
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis Kris V. Kowdley, Stuart C. Gordon, K. Rajender Reddy, New England Journal of Medicine	2014	1.1K
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options Ira M. Jacobson, Stuart C. Gordon, Kris V. Kowdley, New England Journal of Medicine	2013	1.1K
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Eric Lawitz, Mark Sulkowski, Reem Ghalib, The Lancet HepatologyHepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy	2014	814
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3 Stefan Zeuzem, Geoffrey Dusheiko, Riina Salupere, New England Journal of Medicine	2014	796
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward Gane, Catherine Stedman, Robert H. Hyland, New England Journal of Medicine	2013	754
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Eric Lawitz, Fred Poordad, Phillip S. Pang, The Lancet HepatologyHepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy	2013	546

Page 1